Pyxis Oncology Q2 FY26 net loss widens to $25.3 million

Reuters2026/08/13 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pyxis Oncology posted a GAAP net loss of USD 25.3 million, or USD 0.40 a share, for Q2 2026.
R&D expense edged down to USD 16.1 million; manufacturing costs fell, partly offset by higher MICVO trial and preclinical spending.
G&A expense climbed to USD 9.9 million on higher severance costs and stock-based compensation.
Cash, restricted cash, and short-term investments totaled USD 34.5 million at June 30; upfront private placement proceeds extended runway into Q2 2027.
MICVO monotherapy update in 2L+ R/M HNSCC due in Fall 2026; MICVO-Keytruda combination update targeted for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9808979) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pyxis Oncology Q2 FY26 net loss widens to $25.3 million

You may also like

Crypto prices